view more →
AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)
view more →
Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. Acquired by PerkinElmer (NYS: PKI) in March 2011.
view more →
Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform. Acquired by Press Ganey Associates in January 2018.
view more →
Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).
view more →
Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.
view more →
Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.
view more →
Provider of genomic and biomedical computing platform intended to empower scientists and clinicians. Acquired by Veritas Genetics in August 2017.
view more →
CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. IPO in June 2021 (NASDAQ: CVRX).
view more →
Developer of a technology designed to extract highly sensitive nucleic acid quantification. Acquired by Bio-Rad 2021
view more →
Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.
view more →
The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs. IPO in May 2017 (NASDAQ: GTHX).
view more →
Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. IPO in September 2020 (NASDAQ: GRAY).
view more →
Provider of a histotripsy platform designed for the treatment of cancer. Acquired by Bezos Expeditions, Wellington K5 Global 2025
view more →
Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.
view more →
Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024
view more →
Kymera is developing a heterobifunctional small molecule drug platform. IPO in August 2020 (NASDAQ: KYMR).
view more →
Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.
view more →
Provider of patient experience platform designed to facilitate the relationship between physicians and patients. Acquired by NextGen 2019
view more →
Developer of staffing, communication and schedule management tools designed to modernize staffing processes. Acquired by HealthStream 2020
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
view more →
A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. Acquired by Shionogi 2023
view more →
Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. Acquired by NASDAQ: ALKS in Nov 2019
view more →
Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)
view more →
Standard Bariatrics is developing a clamp and stapler to standardize sleeve gastrectomy procedures. Acquired by Teleflex in September 2022.
view more →
Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023
view more →
The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025
view more →
Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.
view more →
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
